C Jackisch, M Untch, D Chatsiproios, C Lamparter, F Overkamp, W Lichtenegger, W Rönsberg, C Thomssen, G von Minckwitz
{"title":"[乳腺癌:德国2004年治疗质量分析:Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)回顾性调查]。","authors":"C Jackisch, M Untch, D Chatsiproios, C Lamparter, F Overkamp, W Lichtenegger, W Rönsberg, C Thomssen, G von Minckwitz","doi":"10.1055/s-2006-955230","DOIUrl":null,"url":null,"abstract":"<p><p>The Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) conducted a nationwide 3-phase analysis of the care structure and standard of therapy given to patients with breast cancer from 2002 (4th quarter) to 2004 (4th quarter). The analysis includes 1069 patients from 257 institutions; 34% with early breast cancer and 66% with metastatic disease. No reliable data on the pattern of care of these patients have been published to date in Germany. The extent to which national and international therapy recommendations were implemented in routine clinical practice was unclear. Evaluation of the data shows that treatment based on the guidelines is now being implemented very reliably in certain sectors. This is of particular relevance to the pattern of adjuvant treatment in early breast cancer. At that time 68 % of the patients received an anthracyclin based chemotherapy and in addition 18% received an anthracycline and taxane based chemotherapy. Participation in clinical trials peaked with 30% in the neoadjuvant setting. The problem with metastatic breast cancer is the complexity of the interdisciplinary treatment involved. The present analysis conducted by the AGO was the first attempt to analyse the treatment given to metastatic patients and to systematise the approach to treatment. The fundamental problem remains, irrespective of the stage of the tumour, namely that too few patients are treated in randomised clinical studies.</p>","PeriodicalId":23881,"journal":{"name":"Zentralblatt fur Gynakologie","volume":"128 6","pages":"352-61"},"PeriodicalIF":0.0000,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-2006-955230","citationCount":"4","resultStr":"{\"title\":\"[Breast cancer: analysis of treatment quality in Germany 2004: retrospective survey by Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)].\",\"authors\":\"C Jackisch, M Untch, D Chatsiproios, C Lamparter, F Overkamp, W Lichtenegger, W Rönsberg, C Thomssen, G von Minckwitz\",\"doi\":\"10.1055/s-2006-955230\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) conducted a nationwide 3-phase analysis of the care structure and standard of therapy given to patients with breast cancer from 2002 (4th quarter) to 2004 (4th quarter). The analysis includes 1069 patients from 257 institutions; 34% with early breast cancer and 66% with metastatic disease. No reliable data on the pattern of care of these patients have been published to date in Germany. The extent to which national and international therapy recommendations were implemented in routine clinical practice was unclear. Evaluation of the data shows that treatment based on the guidelines is now being implemented very reliably in certain sectors. This is of particular relevance to the pattern of adjuvant treatment in early breast cancer. At that time 68 % of the patients received an anthracyclin based chemotherapy and in addition 18% received an anthracycline and taxane based chemotherapy. Participation in clinical trials peaked with 30% in the neoadjuvant setting. The problem with metastatic breast cancer is the complexity of the interdisciplinary treatment involved. The present analysis conducted by the AGO was the first attempt to analyse the treatment given to metastatic patients and to systematise the approach to treatment. The fundamental problem remains, irrespective of the stage of the tumour, namely that too few patients are treated in randomised clinical studies.</p>\",\"PeriodicalId\":23881,\"journal\":{\"name\":\"Zentralblatt fur Gynakologie\",\"volume\":\"128 6\",\"pages\":\"352-61\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1055/s-2006-955230\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zentralblatt fur Gynakologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-2006-955230\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zentralblatt fur Gynakologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-2006-955230","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
摘要
Organgruppe Mamma der Arbeitsgemeinschaft gynecologische Onkologie (AGO)对2002年(第四季度)至2004年(第四季度)全国乳腺癌患者的护理结构和治疗标准进行了三阶段分析。该分析包括来自257家机构的1069名患者;34%为早期乳腺癌66%为转移性疾病迄今为止,在德国还没有发表过关于这些患者护理模式的可靠数据。国家和国际治疗建议在常规临床实践中的实施程度尚不清楚。对数据的评价表明,目前在某些部门非常可靠地实施了基于准则的治疗。这与早期乳腺癌的辅助治疗模式特别相关。当时68%的患者接受了基于蒽环类药物的化疗,另外18%的患者接受了基于蒽环类药物和紫杉烷的化疗。在新辅助治疗中,临床试验的参与率达到了30%。转移性乳腺癌的问题在于涉及的跨学科治疗的复杂性。目前由AGO进行的分析是第一次尝试分析给予转移性患者的治疗并使治疗方法系统化。无论肿瘤处于何种阶段,根本问题仍然存在,即在随机临床研究中接受治疗的患者太少。
[Breast cancer: analysis of treatment quality in Germany 2004: retrospective survey by Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)].
The Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) conducted a nationwide 3-phase analysis of the care structure and standard of therapy given to patients with breast cancer from 2002 (4th quarter) to 2004 (4th quarter). The analysis includes 1069 patients from 257 institutions; 34% with early breast cancer and 66% with metastatic disease. No reliable data on the pattern of care of these patients have been published to date in Germany. The extent to which national and international therapy recommendations were implemented in routine clinical practice was unclear. Evaluation of the data shows that treatment based on the guidelines is now being implemented very reliably in certain sectors. This is of particular relevance to the pattern of adjuvant treatment in early breast cancer. At that time 68 % of the patients received an anthracyclin based chemotherapy and in addition 18% received an anthracycline and taxane based chemotherapy. Participation in clinical trials peaked with 30% in the neoadjuvant setting. The problem with metastatic breast cancer is the complexity of the interdisciplinary treatment involved. The present analysis conducted by the AGO was the first attempt to analyse the treatment given to metastatic patients and to systematise the approach to treatment. The fundamental problem remains, irrespective of the stage of the tumour, namely that too few patients are treated in randomised clinical studies.